Latest Asx News

AdNeo Limited reports sustained positive cash flow and strong contract wins, advancing its strategic acquisition of Learnt Global ahead of schedule while securing $5.5 million in new capital.

Garda Property Group’s FY25 results reveal a strategic pivot with significant asset sales and a sharp reduction in gearing, setting the stage for an 11% rise in distributions in FY26.

Forrestania Resources has voluntarily suspended trading on the ASX as it prepares to announce a significant acquisition, signaling a potentially transformative move for the mining company.

Flynn Gold’s latest diamond drilling at the Trafalgar Prospect within its Golden Ridge Project reveals multiple high-grade gold veins, reinforcing the prospect’s geological model and potential scale. The company plans further drilling to refine resource estimates.

BPH Global confirms that the seaweed Sesuvium portulacastrum accumulates valuable metals including gold and lithium, but shifts focus to biological extraction after chemical methods fall short.

White Cliff Minerals confirms significant high-grade copper and silver mineralisation at its Danvers prospect, raising A$14.4 million to fund expanded exploration. The company also announces a strategic board appointment as it advances its Rae Copper and Great Bear projects.

Syrah Resources has launched a fully underwritten A$70 million equity raising to support its Balama graphite operations and Vidalia Active Anode Material facility, alongside securing a two-year forbearance on its US Department of Energy loan. The company advances commercial qualification of Vidalia AAM amid strong demand and US tariff support.

Syrah Resources has launched a A$70 million equity raising and secured a two-year forbearance on its US Department of Energy loan, bolstering its cash position and operational flexibility amid ongoing challenges.

Otto Energy has completed a $38.4 million capital return while maintaining steady oil production despite a dip in gas output. The company also announced the resignation of its Acting CEO, signaling a period of transition.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Arizona Lithium has secured regulatory approval for Phase 1 production at its Prairie Lithium Project in Saskatchewan and raised $4.25 million through an oversubscribed share purchase plan, marking key milestones toward commercial lithium extraction.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.